Testicular endocrine function and cyclophosphamide in prepubertal and pubertal patients

Area of Science:

• Pediatric Endocrinology
• Oncology
• Nephrology

Background:

• Cytostatic therapy, including cyclophosphamide, is crucial for treating leukemia, malignant tumors, and nephrotic syndrome in pediatric patients.
• Concerns exist regarding the potential long-term effects of such treatments on reproductive health, particularly testicular function.
• Leydig cells are vital for testosterone production, a key indicator of testicular endocrine function.

Purpose of the Study:

• To evaluate the impact of cyclophosphamide treatment on Leydig cell function in prepubertal and pubertal patients.
• To assess testicular endocrine function through human chorionic gonadotropin (HCG)-stimulation tests.
• To determine if cyclophosphamide has a damaging effect on Leydig cell function.

Main Methods:

• HCG-stimulation tests were administered to assess Leydig cell reserve and function.
• Urinary testosterone levels were measured as a primary biomarker of Leydig cell activity.
• The study included pediatric patients undergoing cytostatic therapy for leukemia/malignant tumors and those with nephrotic syndrome post-treatment.

Main Results:

• Urinary testosterone assays showed no significant reduction in Leydig cell function.
• Testicular function, as indicated by testosterone response to HCG stimulation, was preserved.
• No damaging effect of cyclophosphamide on Leydig cell function was observed in the studied patient groups.

Conclusions:

• Cyclophosphamide treatment, as used in this cohort, does not appear to adversely affect Leydig cell function in pediatric patients.
• Preserved Leydig cell function suggests that cyclophosphamide may not cause significant long-term endocrine testicular damage in these patients.
• Further long-term studies may be warranted to fully elucidate the reproductive health outcomes.